XOMA Royalty to Report Fourth Quarter and Full Year 2025 Financial Results on March 18, 2026
Rhea-AI Summary
XOMA Royalty (NASDAQ: XOMA) will report fourth quarter and full year 2025 financial results on Wednesday, March 18, 2026. The company will host a live webcast on March 18, 2026 at 8:00 AM ET to discuss results and provide a business update.
According to the company, the webcast will be accessible on the Investors "News & Events" page and a replay will be available for 30 days after the live event.
Positive
- None.
Negative
- None.
News Market Reaction – XOMAP
In the Mar 12 session, XOMAP declined 0.13%, reflecting a mild negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Feb 18 | Investor conferences | Neutral | -1.3% | Planned management presentations and 1x1 meetings at March investor conferences. |
| Feb 09 | Acquisition closed | Positive | +0.4% | Completion of tender offer and acquisition of Generation Bio, adding royalty assets. |
| Jan 12 | CFO transition | Negative | -1.5% | Longtime CFO stepping down and appointment of new CFO from other biotechs. |
| Dec 30 | Royalty restructuring | Neutral | +0.0% | Amended Takeda collaboration, trading mezagitamab economics for basket of assets. |
| Dec 22 | Preferred dividends | Positive | +0.4% | Declaration of quarterly cash dividends on Series A and Series B preferred shares. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Recent corporate and transaction news has generally seen modest, directionally consistent price reactions, with no extreme moves following announcements.
Over the past several months, XOMA Royalty has focused on portfolio-building and capital allocation. It completed acquisitions of HilleVax and Turnstone Biologics (via earlier 8-K filings) and, more recently, closed the Generation Bio acquisition, with a 0.39% positive reaction. Corporate actions included a CFO transition on Jan 12, 2026 and a strategic royalty-sharing amendment with Takeda on Dec 30, 2025. For XOMAP holders, preferred dividends declared on Dec 22, 2025 supported income visibility. Today’s earnings date notice fits into this cadence of steady, event-driven updates.
AI-generated analysis. How Rhea-AI works. Not financial advice.
EMERYVILLE, Calif., March 12, 2026 (GLOBE NEWSWIRE) -- XOMA Royalty Corporation (NASDAQ: XOMA), the biotech royalty announced today it will report fourth quarter and full year 2025 financial results on Wednesday, March 18. The Company will host a webcast on March 18, 2026, at 8:00 am Eastern Time to discuss the results and provide a business update.
The webcast will be accessible on the “News & Events” page in the Investors section of XOMA Royalty’s website (www.investors.xoma.com/news-events). A replay of the webcast will be available for 30 days following the live event.
About XOMA Royalty Corporation
XOMA Royalty is a biotechnology royalty aggregator playing a distinctive role in helping biotech companies achieve their goal of improving human health. XOMA Royalty acquires the potential future economics associated with pre-commercial and commercial therapeutic candidates that have been licensed to pharmaceutical or biotechnology companies. When XOMA Royalty acquires the future economics, the seller receives non-dilutive, non-recourse funding they can use to advance their internal drug candidate(s) or for general corporate purposes. The Company has an extensive and growing portfolio of assets (asset defined as the right to receive potential future economics associated with the advancement of an underlying therapeutic candidate). For more information about the Company and its portfolio, please visit www.xoma.com or follow XOMA Royalty Corporation on LinkedIn.
| Investor contact: | Media contact: |
| Juliane Snowden | Kathy Vincent |
| XOMA Royalty Corporation | KV Consulting & Management |
| +1-646-438-9754 | kathy@kathyvincent.com |
| juliane.snowden@xoma.com | |